Aquestive Therapeutics, Inc. filed a Form 8-K on November 16, 2026, disclosing an investor presentation delivered at the Jefferies Global Healthcare Conference on that same date.
Key Highlights
- Filing type: Current Report under Item 7.01 Regulation FD Disclosure, dated November 16, 2026
- Exchange listing: Common Stock (par value $0.001 per share) trades on NASDAQ:AQST on the Nasdaq Global Market
- Conference presentation: An investor presentation was given at the Jefferies Global Healthcare Conference on November 16, 2026, and is attached as Exhibit 99.1
- Signing officer: The report was signed by A. Ernest Toth, Jr., Chief Financial Officer
- Not "filed" for liability purposes: The filing states the information in Item 7.01 "shall not be deemed to be 'filed' for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934"
Aquestive Therapeutics Discloses Jefferies Conference Presentation Under Regulation FD
Aquestive Therapeutics, Inc., a Delaware-incorporated pharmaceutical company headquartered at 184 Liberty Corner Road, Suite 305, Warren, NJ, filed a Current Report on Form 8-K with the SEC on November 16, 2026. According to the filing, the report was submitted in connection with the disclosure of an investor presentation shared at the Jefferies Global Healthcare Conference on that date. The presentation was provided to institutional investors, analysts, and others, and was attached to the filing as Exhibit 99.1.
The company disclosed the presentation under Item 7.01 Regulation FD, which governs the fair disclosure of material nonpublic information to market participants. The filing noted that "this information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means." The report explicitly states that the contents of Item 7.01, including Exhibit 99.1, are not deemed "filed" under Section 18 of the Exchange Act and are not automatically incorporated by reference into other filings unless expressly stated.
Aquestive Therapeutics is listed on the Nasdaq Global Market under the ticker NASDAQ:AQST, with common stock carrying a par value of $0.001 per share. The filing was signed on behalf of the registrant by A. Ernest Toth, Jr., in his capacity as Chief Financial Officer. The company's Commission File Number is 001-38599, and its I.R.S. Employer Identification Number is 82-3827296.
What Was Disclosed
Aquestive Therapeutics filed an 8-K on November 16, 2026, furnishing an investor presentation from the Jefferies Global Healthcare Conference as Exhibit 99.1 under Regulation FD. The presentation content was not reproduced within the 8-K body itself.




Please wait processing your request...